Corbus Pharmaceuticals Holdings, Inc. announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application of CRB-601, a potentially best-in-class TGFß blocking monoclonal antibody targeting the integrin avß8. Pre-clinical data presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) demonstrates CRB-601 overcame tumor immune exclusion and enhanced the activity of immune checkpoint inhibitors in vivo. The Company expects to enroll the first participant in a Phase 1 study in the first half of 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.2 USD | -6.89% | +7.19% | +662.91% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+662.91% | 510M | |
+7.65% | 115B | |
+12.72% | 107B | |
-13.44% | 22.31B | |
-3.99% | 21.6B | |
-6.59% | 18.23B | |
-39.93% | 17.62B | |
+6.76% | 14.26B | |
+32.90% | 12.37B | |
-27.78% | 8.28B |
- Stock Market
- Equities
- CRBP Stock
- News Corbus Pharmaceuticals Holdings, Inc.
- Corbus Pharmaceuticals Holdings, Inc. Announces FDA Clearance of IND Application for its Anti-avb8 Monoclonal Antibody (CRB-601)